The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     
 


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Diaz, M.
Right arrow Articles by R. Klinman, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Diaz, M.
Right arrow Articles by R. Klinman, N.
The Journal of Immunology, 2001, 167: 327-335.
Copyright © 2001 by The American Association of Immunologists

Decreased Frequency of Somatic Hypermutation and Impaired Affinity Maturation but Intact Germinal Center Formation in Mice Expressing Antisense RNA to DNA Polymerase {zeta}1

Marilyn Diaz2,*, Laurent K. Verkoczy*, Martin F. Flajnik{dagger} and Norman R. Klinman*

* Department of Immunology, The Scripps Research Institute, La Jolla, CA, 92037; {dagger} Department of Microbiology and Immunology, University of Maryland, Baltimore, MD 21201


    Abstract
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
To examine a role of DNA polymerase {zeta} in somatic hypermutation, we generated transgenic mice that express antisense RNA to a portion of mouse REV3, the gene encoding this polymerase. These mice express high levels of antisense RNA, significantly reducing the levels of endogenous mouse REV3 transcript. Following immunization to a hapten-protein complex, transgenic mice mounted vigorous Ab responses, accomplished the switch to IgG, and formed numerous germinal centers. However, in most transgenic animals, the generation of high affinity Abs was delayed. In addition, accumulation of somatic mutations in the VH genes of memory B cells from transgenic mice was decreased, particularly among those that generate amino acid replacements that enhance affinity of the B cell receptor to the hapten. These data implicate DNA polymerase {zeta}, a nonreplicative polymerase, in the process of affinity maturation, possibly through a role in somatic hypermutation, clonal selection, or both.


    Introduction
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Immunization leads to both the production of serum Abs and the generation of memory B cells that enhance the immune response upon subsequent exposure to Ag. Memory B cells are more abundant than the B cells responsive during an initial response, and when activated, secrete Abs with higher affinity to the immunizing Ag (1, 2, 3). The Ag-specific affinity maturation of memory B cells is primarily a result of somatic hypermutation of V genes and selection for high affinity variants in germinal centers (GCs)3 (4, 5, 6, 7, 8, 9, 10). The molecular basis of somatic hypermutation remains elusive, but recent discoveries suggest a role for transcription or transcription-related factors, such as the heavy chain and the {kappa} intronic enhancers (11, 12, 13), and for the introduction of nicks or double-strand breaks (DSBs) (14, 15, 16). Recently, a novel molecule with homology to RNA deaminases (activation-induced cytidine deaminase, AID) was implicated in somatic hypermutation, although its role may lie in the modification of transcripts encoding molecules important to this mechanism (17). These data suggest a multilayered mechanism that includes at least 1) targeting of a lesion to the V region by transcription or transcription-related factors, and 2) introduction of nicks or DSBs to Ig V genes followed by error-prone synthesis.

Studies of the pattern of V region mutations in nonselected sequences such as in passenger transgenes, synonymous substitutions, and nonproductively rearranged alleles reveal a bias to generate transitions and base substitutions, the hotspot sequence RGWY, and some degree of targeting to one of the DNA strands (18, 19, 20, 21, 22, 23). Furthermore, sequences predicted to generate secondary structure are frequently associated with base substitutions and the few insertions and deletions detected in hypermutated sequences (19, 24, 25, 26, 27). In sharks, in which the pattern of mutation of new Ag receptor genes (28) is otherwise similar to that of mice and human Ig, doublets are frequently found even in the framework regions (18). The mutation frequency, the enhancement of mutability by secondary structure, and the transition bias implicate a role for error-prone polymerase activity in somatic hypermutation, as originally proposed by Brenner and Milstein (29). The high frequency of doublets in the shark new Ag receptor mutants implies extension from a mismatched base pair, and such data, together with the predominance of base substitutions, suggest that the error-prone activity may be dependent on DNA polymerase {zeta} (Pol {zeta}) (18, 30, 31). Pol {zeta} catalyzes the bypass of DNA lesions that normally stall replication forks (32). Its ability to recognize (or to at least "ignore") unconventional bases, such as those chemically modified by mutagens, makes it moderately prone to insert incorrect bases, but its most prominent characteristic lies in extension beyond a mismatched base pair (33, 34, 35). Indeed, it was recently demonstrated that Pol {zeta} extends synthesis beyond mismatched base pairs created by other distributive error-prone polymerases, such as Pol {iota} (34) and {eta} (36). Furthermore, there is evidence that this polymerase plays a role in the mutagenic repair of DSBs. In yeast, the great majority of base substitutions introduced near a DSB are the result of Pol {zeta} activity (37), suggesting that it may also play a role in DSB repair. Therefore, recent evidence suggesting that DNA DSBs are intermediate products of somatic hypermutation also implicates this polymerase in Ig hypermutation.

Knockout mice lacking Pol {zeta} are early embryonic lethals (38, 39, 40). Reasoning that a small amount of Pol {zeta} may overcome the lethality of the knockout, we have generated transgenic (Tg) mice that express antisense transcripts to the RNA encoding the catalytic subunit of this polymerase (mouse REV3, mREV3). These mice appear healthy, express high levels of antisense RNA, and display very low levels of mREV3 transcript. Here, we examine somatic hypermutation and affinity maturation in these mice following immunization with a hapten-protein complex. Our findings indicate that, in these mice, the overall mutation frequency is decreased and affinity maturation is delayed, but GC formation and other aspects of the immune response appear unaffected.


    Materials and Methods
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Generation of Tg mice

To generate mice that express antisense transcripts to the mREV3 gene, 870 bp of a portion of the REV3 gene was cloned into the XhoI site of the pCXN2 expression vector (41) downstream of the CMV enhancer and the chicken {beta}-actin promoter (Fig. 1GoA). Because the transcriptional regulation of endogeneous REV3 is unknown, we selected a promoter-enhancer combination with constitutive expression and a highly stable 3' untranslated region (rabbit {beta}-globin). Furthermore, we reasoned that using a powerful expression vector that generates highly stable transcripts would maximize the possibility of duplex formation and degradation of the REV3 target transcript. The insert was generated by amplifying a portion of the mouse REV3 gene with oligonucleotides Zetf (5'-GAGATTCAGATGCACTCCTGG-3') and Zetr (5'-GTCCTGCTTGTAAGACTTCAT3-'), digestion of the PCR product with XhoI, and then ligation to the vector (1:5 vector:insert ratio) with T4 DNA ligase. Competent cells (INV-{alpha}F'; Invitrogen, Carlsbad, CA) were transformed with ligation product and grown in Luria-Bertani agar plates according to the protocol for the original TA cloning kit (Invitrogen). To release the unit core of the expression vector (3.3 kb), a plasmid with an insert in the antisense orientation was digested with HindIII and SalI, and the 3.3-kb piece containing the insert was gel purified with the gene-cleaning kit (Bio 101, Vista, CA). The contructs were microinjected into fertilized eggs of C57BL/6 background at The Scripps Research Institute Transgenic Facility (La Jolla, CA) by standard procedures. Mice were screened for the presence of the transgene by PCR of genomic DNA and RT-PCR of tail RNA with oligonucleotides 2eTRN (5'-TCTTGGTAGAACACCCTTTCG-3'), which complements a portion of the mouse REV3 insert, and RBGR (5'-TGATAGGCAGCCTGCACCTGA-3'), complementing the rabbit 3' untranslated region in the vector.



View larger version (28K):
[in this window]
[in a new window]
 
FIGURE 1. A, Schematic diagram of construct used to generate mREV3 antisense-Tg mice. The construct contains an 870-bp portion of the mREV3 (Pol-{zeta} catalytic subunit gene) cDNA cloned in reverse orientation downstream of the CMV enhancer/chicken {beta}-actin promoter. The full-length 10,459-bp mREV3 cDNA is also shown to demonstrate the C-terminal polymerase domain-containing region from which the antisense cDNA fragment was derived. Restriction sites are as follows: X, XhoI; S, SalI; and H, HindIII. B, Breeding scheme to generate high expressors of the transgene from the initial founder. Animals used in this study are encircled and coded for whether they were analyzed 15 or 30 days after immunization.

 
DNA isolation and Southern analysis

To assess the number of integration sites, genomic DNA from the founder was isolated from the tail by phenol-chloroform extraction and digested separately with BamHI and HindIII. Southern hybridization procedures were performed under both high and intermediate stringency conditions, as described previously (42), using the above-described PCR product for the transgene as 32P-labeled probe.

Mice and immunization

Limulus polyphemus hemocyanin (Hy) (Sigma, St Loius, MO) and BSA (Biosearch Technologies, Somerville, NJ) were conjugated to DNP and (4-hydroxy-3 nitrophenyl)acetyl (NP) haptens as previously described (3, 43). Control C57BL/6 mice, obtained from the National Institutes of Health, and Tg mice that were 8–12 wk old were immunized either i.p. with 50 µg NP10-Hy suspended in alum or i.p. and in multiple s.c. sites with 100 µg NP10-Hy suspended in CFA (Sigma).

Flow cytometry of bone marrow, spleen, and thymus

Bone marrow cells were obtained from the femur by rinsing the cells out of the bone marrow with a syringe containing HBSS. Spleen cells were dispersed in a culture dish with HBSS by grinding the tissue with the back of a 3-cc syringe. Dispersed spleen or bone marrow cells in HBSS were filtered through a Nytex (Tetko, Lancaster, NY) membrane into a culture tube. Following one round of centrifugation at 1500 rpm for 7 min, RBCs were lysed with 4 ml of 0.83% ammonium chloride at room temperature for 4 min. HBSS was added to bring the volume to 15 ml, and the cells were centrifuged at 1500 rpm for 7 min. Cells were resuspended in HBSS with 0.1% BSA and 0.02% azide to a concentration of 106 ml. Spleen cells from naive mice were stained with anti-heat-stable Ag-FITC (M1/69; BD PharMingen, San Diego, CA) and anti-B220-CyChrome (RA3-6B2; BD PharMingen) at 0.5–1.0 µg/106 cells. For mutation analysis, cells from approximately half a spleen from mice immunized with 50 µg NP-Hy suspended in alum were prepared 15 days after immunization as described above, but stained with anti-{lambda}-FITC (R26-46; BD PharMingen) and anti-B220-PE (RA3-6B2; BD PharMingen) Abs (0.5–1.0 µg of Ab per 106 cells). Bone marrow cells from same immunized mice were stained with anti-CD43-PE (S7; BD PharMingen) and anti-B220-CyChrome (RA3-6B2; BD PharMingen) at the same concentrations used for spleen cells.

T cells were obtained from thymus by grinding as described above for spleen cells, centrifuged at 1500 rpm for 7 min at 4°C, and resuspended in degassed HBSS with 0.1% BSA and 0.02% azide. Cells were stained with anti-CD4-FITC (L3T4) and anti-CD8-CyChrome Abs (53-6.7) (BD PharMingen) at 0.5–1.0 µg of Ab per 106 cells for FACS analysis.

Quantitation of Ab concentration and relative affinities

Serum Abs were quantified using a fluorescence ELISA previously described (43). In brief, 25 µl of a 1/50–1/8000 dilution of serum was added to microtiter plates coated with NP-BSA or DNP-BSA and incubated overnight. The plates were washed, and bound Abs were quantified by the addition of alkaline phosphatase-labeled goat anti-{kappa}, -{lambda}, -{gamma}, or -µ, and the fluorescent substrate 4-methylumbelliferylphosphate (Boehringer Mannheim, Indianapolis, IN). Standard curves were constructed using 1–80 µg of the purified anti-NP hybridoma protein B-1-8 (for {lambda}) (44) and the anti-DNP hybridoma 109.3 on DNP plates for {kappa} and {gamma} (45).

To determine relative affinities, hapten inhibition assays were done as described previously (43, 44). Briefly, 25 µl of a 1/200–1/2000 dilution of serum obtained 15 days after immunization from mice immunized with NP-Hy in alum were mixed with NP cappoate (Biosearch Technologies) at concentrations ranging from 6 x 10-5 to 6 x 10-8 M and added to individual wells of NP4-BSA-coated microtiter plates. Bound anti-NP IgG Abs were quantified by fluorescence ELISA using alkaline phosphatase-labeled goat anti-mouse IgG Abs (Caltag, Burlingame, CA). The inhibition of Ab binding was calculated as described previously (43), and the concentration of free hapten yielding IC50 of Ab binding was estimated from semilog plots.

In vitro spleen fragment culture

To quantify and analyze responsiveness of memory B cells at the clonal level, cells from immunized mice were transferred to irradiated carrier-primed recipients for establishment of fragment cultures, as previously described (46). Briefly, two million total spleen lymphocytes isolated from mice immunized 30 days earlier with 100 µg NP10-Hy in CFA were injected into lethally irradiated carrier-primed BALB/b recipients. Sixteen hours later, recipient spleens were removed, and 1 mm3-fragments were prepared and placed in microtiter wells with 10-6 M NP10-Hy for 2 days at 37°C. At days 6, 7, and 12, culture fluids were analyzed by ELISA (see above) for the presence of µ, {gamma}, {lambda}, and/or {kappa} NP-specific Abs. Each fragment that was positive for {gamma} and {lambda} Abs was dispersed, and recovered cells were aliquoted into two samples for RT-PCR analysis of VH186.2 (see RNA isolation, reverse transcription, and PCR amplification).

GC staining

Spleens from immunized mice were cut in half, and one half was covered with OCT medium in a cryomold and placed on dry ice. Then 6- to 8-µm sections were cut with a Cryostat (CM1800; Leica, Deerfield, IL). The sections were fixed with cold acetone for 30 s. Each slide was incubated in a MeOH-hydrogen peroxide solution (4:1) for 20 min and then washed for 10 min in PBS. Slides were incubated in 1/500 biotinylated peanut lectin agglutinin (PNA; 5 mg/ml) (Biomedia, Foster City, CA) in PBS for 1 h at room temperature, rinsed with PBS, and incubated for 10 min with streptavidin-HRP in PBS (1/500) (Jackson ImmunoResearch, West Grove, PA). After a rinse with PBS for 10 min, chromogen (0.01% hydrogen peroxide, 1 mg diaminobenzidine, and 0.05 M Tris (pH 7.2)) was added, and slides incubated for 2–20 min.

RNA isolation, reverse transcription, and PCR amplification

To isolate RNA from {lambda}+B220+ total spleen cells or cells isolated from fragment cultures, cells were pelleted, resuspended in 200 µl TRIzol (Life Technologies, Rockville, MD) and lysed by repeated pipeting. To isolate RNA from spleen tissues, small spleen pieces were placed in 100 µl TRIzol, glass beads were added, and the tissue was homogenized with a Mini-BeadBeater (Biospec Products, Bartlesville, OK). RNA was isolated from all samples according to the TRIzol maufacturer specifications. cDNA was made with the Superscript II kit (Life Technologies) according to the protocol of the manufacturer. For mutation analysis of VH186.2, cDNA was amplified first for 30 cycles (1 min at 94°C, 45 s at 58°C, and 45 s at 72°C) with Taq polymerase (Life Technologies), primers complementing the leader region of V genes of the J558 family (leader (forward), 5'-CATGGAATTCTTGGCAGCAACAGCTACAGG-3') and a portion of the {gamma} C1 domain (onk335, 5'-TCCCTGAAGCTTATTTTCTTGTCCACCTTG-3'). A second 22-cycle round of PCR was done (1 min at 94°C, 45 s at 60°C, and 45 s at 72°C) with 1 µl PCR product from the first reaction using the forward leader and an internal oligonucleotide complementing a region proximal to the J region in the {gamma} C1 domain (onk14, 5'-TCCAAAGCTTGGGGCCAGTGGATAGAC-3'). To estimate the Taq polymerase error rate, a plasmid containing an insert with the germline VH186.2 sequence was amplified as described above, and our estimated Taq polymerase error rate was 1/10,000 bases.

For expression analysis, primers complementing the transgene (endogenous REV3) that do not overlap with the REV3 region in the transgene were used and are described as follows: (Zetf, described above; PolZr, 5'-GGCATTGAGCATCCGTGACAG-3'); and the housekeeping gene hypoxanthine phosphoribosyltransferase (HPRT) (HPRTMf, 5'-CCTCATGGACTGATTATGGAC-3'; HPRTMr, 5'-GTCAAGGGCATATCCAACAAC-3'). These primers were used in 24-cycle reactions (1 min at 94°C, 45 s at 60°C, and 45 s at 72°C). For cloning purposes, the 5' end of the forward leader, onk335, and onk14 primers were slightly modified to acomodate restriction sites for either HindIII or EcoRI.

Cloning and sequencing of samples

PCR product was purified with the PCR purification kit (Qiagen, Chatsworth, CA) and digested with HindIII and EcoRI. Ligation and transformation of digested product into Top10F'-competent cells was done according to the manufacturer specifications for the vector (pZero cloning vector; Invitrogen). To isolate plasmids, cells from colonies were treated with lysozyme and boiled for 40 s, followed by centrifugation and precipitation of plasmid DNA with isopropanol. The insert was sequenced with 35S, a primer complementing the SP6 site in the vector, and T4 sequenase (US Bioscience, West Conshohocken, PA), and the sequenced product was run in a 6% polyacrylamide gel. Sequences were analyzed with the DNasis software (Hitachi Software Engineering, Tokyo, Japan). The entire length of the V region including the complementarity-determining region (CDR)3 (310–330 bps) was sequenced for the vast majority of the clones.

Statistical tests used to analyze mutation frequencies are described by Sokal and Rohlf (47).


    Results
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
High expression of antisense RNA to mREV3 in Tg mice with a concordant decrease in endogenous REV3 mRNA levels

Of 10 antisense REV3-Tg founder mice, only 1 expressed the transgene at high levels. Southern hybridization of genomic DNA from this mouse revealed two integration sites, each with, at most, two copies of the transgene (Fig. 2GoA). The fact that only one line expressed the transgene and that so few Tg animals were recovered may reflect strong selection during embryonic development for Tg animals that did not completely lose expression of the REV3 gene (it is possible that animals with large copy numbers of the transgene, as is often seen during transgene integration, were embryonic lethals). A line of mice expressing significant levels of the antisense product was then generated through a series of backcrosses (Fig. 1GoB). All animals used in this study had at least two copies of the transgene, either as heterozygotes at both integration sites or as homozygotes at one of the integration sites (Fig. 2GoA). To test for transgene expression in B cells, RT-PCR was done on bone marrow and splenic B cells. A high level of expression of the transgene in B cells was detected in all Tg animals used in this study (Fig. 2GoB).



View larger version (56K):
[in this window]
[in a new window]
 
FIGURE 2. A, BamHI and HindIII restriction digests of genomic DNA revealed two integration sites. The minimum size of the transgene is ~3.3 kb and lacks internal sites for either of the restriction enzymes used. Therefore, the two integration sites are likely to contain a single copy of the transgene. B, Transgene expression by RT-PCR in Tg animals used in this study. The source of cDNA for lanes 1, 2, 4, and 5 was sorted B220+{lambda}+ cells; for lanes 3, 6, 7, and 8, the source was total spleen cells; for lane 9, the source was Peyer’s patches; and lanes 10 and 11 are RNA from B220+{lambda}+ cell from two Tg mice to control for genomic contamination of the samples. Expression of the transgene was detected in all tissues tested, including nonlymphoid tissues (data not shown). C, Specific reduction of mREV3 transcripts as assessed by low-cycle (24 cycles) RT-PCR.

 
Antisense RNA can act at various levels including obstructing transcription, degradation of endogenous transcript, and blocking translation (48, 49). Antisense activity by negatively regulating transcription or by transcript degradation predicts decreased levels of the target gene transcript in the mRNA population and need not target the translational start site (as seen for many of the naturally occurring antisense elements, i.e., c-myc gene; 50). Tg mice displayed a reduction in REV3 mRNA to levels barely detectable by RT-PCR amplification (Fig. 2GoC), whereas the levels of the housekeeping genes HPRT, cyclophilin, and G6PD remained similar to controls. This reduction was seen in all Tg animals with more than one copy of the transgene regardless of the tissue analyzed (memory B cells, total spleen, Peyer’s patches, and tail RNA; data not shown).

Mice with low levels of Pol {zeta} appear healthy and of normal body weight and do not seem to have decreased lifespans (the oldest founder is now 23 mo), suggesting that low levels of this polymerase suffice to overcome the embryonic defect seen in the knockout. Given the strong defect early in hematopoeisis in the knockout (38, 39, 40), we analyzed B cell and T cell development in Tg animals. The overall numbers of B cells in the bone marrow were reduced (ranging from 30 to 60%), reflecting a defect that can be seen as early as in the pro-B cell comparment but permeates all later stages of B cell development in the bone marrow as well (Fig. 3Go). Additionally, the number of B cells in the spleen were reduced in young adult mice (20–50% reduction; Fig. 3Go). The nature of the defect in the bone marrow is currently under investigation. The number of T cells in the thymus was nearly normal at all stages of development, with a slight decrease in the percentage (<15% decrease) of CD4 single-positive cells (Fig. 3Go). Histological analysis of the spleen revealed normal morphology in all areas, including the lymphoid compartment.



View larger version (68K):
[in this window]
[in a new window]
 
FIGURE 3. Flow cytometric analysis of B cells in the bone marrow, spleen, and T cells in the thymus of Tg vs control animals. Although there is variation in the severity of the phenotype among Tg animals (the results depicted here are reflective of the more severe end of the spectrum), there is an overall decrease in B cells both in the bone marrow and the spleen in all mice with low levels of mREV3, whereas T cell populations in the thymus appear normal. Heat-stable Ag staining was used in the spleen analysis to evaluate B cell maturity and progenitors of memory B cells (56 ). All analyses were done on nonimmunized Tg and control animals.

 
Humoral immune responsiveness of Tg mice expressing antisense RNA to Pol {zeta}

To examine humoral immune responses in Tg mice, four Tg and four control C57BL/6 mice were immunized i.p. with 0.05 mg NP10-Hy in alum. The immune response of Ighb mice to the NP hapten has been well characterized by a number of laboratories (9, 44, 51, 52). Typically, the mice produce high levels of {lambda}-bearing Abs that predominantly use the heavy chain V gene segment VH186.2, primarily joined to the D segment DH16.1 and the J (JH2) segment. Affinity of the receptor among {lambda}-bearing Abs is most enhanced by a tryptophan (W) to leucine (L) change in VH186.2 amino acid residue 33 in first CDR (52). Late in the response, a different set of highly mutated clones with high affinity arises that is characterized by a glycine (G) in CDR3 residue 99, which is often associated with a lysine (K) to arginine (R) replacement in CDR2 residue 58 (53).

The mice were bled 15 days after immunization and sacrificed for analysis of somatic mutation, GC formation, serum Ab titers, and relative affinities. Both groups of mice mounted a vigorous serum anti-NP Ab response. ELISA analysis indicated that the serum of control and Tg mice contained similar amounts of {lambda} anti-NP Abs. In addition, Tg mice produced comparable quantities of IgG anti NP-Abs (0.55 ± 0.34 mg/ml) with control mice (0.4 ± 0.34 mg/ml), suggesting that neither the levels of specific Ab nor isotype switching was impaired by decreased Pol {zeta} transcripts in Tg mice. The fact that we used a promoter-enhancer combination that induces constitutive expression of the transgene raised the possibility that the reduction of Pol {zeta} occurred in many cell types and, thus, could have exerted an indirect effect on immune responses, particularly if this reduction impacted the "quality" of T cell help. However, T cell development appears relatively normal in Tg mice, and the similar levels of IgG in Tg animals suggest that isotype switch, a mechanism that requires effective T cell help and Ag presentation, was normal.

To examine whether decreased levels of Pol {zeta} had a qualitative impact on the Ab response, the relative affinities of serum Abs from all mice were evaluated by hapten inhibition assays. Although Tg mice had similar amounts of IgG serum Abs, the affinity of NP-specific IgG attained by day 15 after immunization was considerably lower than control mice for three of the four Tg mice (Fig. 4Go). Because of the close correlation of selected mutations and affinity maturation of {lambda} anti-NP Abs, this finding can be explained either by a defect in somatic hypermutation, in the selection for high affinity variants in the GC reaction, or in the generation of memory B cells.



View larger version (18K):
[in this window]
[in a new window]
 
FIGURE 4. Relative affinities of serum Abs to the NP hapten among Tg and control mice immunized with NP-Hy suspended in alum at day 15. Hapten inhibition assays were used to measure relative affinities, and lower free hapten concentrations at IC50 are indicative of high affinity Abs.

 
To evaluate the GC reaction 15 days after immunization, spleens obtained from four Tg and control mice were sectioned and analyzed by PNA staining. Formation of GC was more pronounced in lymphoid follicles of Tg mice as compared with the control mice, and GCs from Tg mice appeared to be larger and more abundant than in controls (Fig. 5Go). GCs were also abundant 30 days after immunization in Tg mice but not in control mice. Large and persistant GCs in antisense REV3 mice is reminiscent of mice deficient in the recently discovered activation-induced cytidine deaminase molecule, which appears to play a role in somatic hypermutation (16).



View larger version (73K):
[in this window]
[in a new window]
 
FIGURE 5. GC staining for PNA+ cells in (A) controls and (B) Tg animals 15 days after immunization with 50 µg of NP-Hy in alum.

 
Although the GC reaction of Tg mice was not compromised, the possibility remained that memory B cell generation was impaired in these mice. We have previously used an analysis of monoclonal responses in spleen fragment cultures to characterize the NP-specific memory B cells in immunized Ighb mice (43, 54). In an analysis comparable with these earlier studies, two antisense-Tg mice and two controls were immunized at multiple sites with 0.1 mg NP-Hy in CFA. Thirty days later, animals were sacrificed, their serum collected and their spleen cells transferred into irradiated carrier-primed recipients, and fragment cultures were established and stimulated with NP-Hy. The frequency of responsive fragments was comparable for cells derived from Tg donors (2.5 responses/1 x 106 transferred cells) vs cells derived from control donors (3 responses/1 x 106 transferred cells). Consistent with a memory B cell phenotype, the majority of responses in both groups produced IgG by day 6 of culture. In contrast, 2 x 106 spleen cells transferred from a naive control mouse yielded 0–0.5 responses/1 x 106 injected spleen cells, the responses were initially IgM+ and were not detectable until day 7. That the responding B cells from immunized Tg mice were in fact memory B cells was confirmed by the presence of somatic mutations in their VH gene segments, which were primarily VH186.2 (albeit, the mutation frequency was lower than in controls; see section below). By these criteria, memory B cell generation appeared unimpaired in Tg mice.

Somatic hypermutation in memory B cells of Tg mice expressing antisense RNA to the gene encoding Pol {zeta}

To determine whether the observed decrease in affinity of serum Abs was the result of a defect in somatic hypermutation, we sequenced the VH186.2-encoded H chain V genes from {lambda}+B220+ B cells obtained from three Tg and three control mice that were immunized with NP-Hy in alum and sacrificed 15 days after immunization. Almost all the clones had at least one mutation, and to ensure that only memory B cells were analyzed, nonmutated sequences were excluded from the analysis. A lower frequency of somatic mutations was detected in the sequences derived from memory B cells of Tg animals when compared with control animals (Fig. 6Go). The lower frequency of mutation appeared not to be due to an inability to generate highly mutated clones, but rather the existence of a population of poorly mutated cells in each of the Tg mice, which was rarely seen in the control animals (62% of Tg clones and 21% of control clones had three mutations or less; Fig. 6Go; Kolmogorov-Smirnov two-sample test, p < 0.001). Importantly, the lower frequency of mutation was accompanied by a highly significant decrease in the proportion of cells that had acquired mutations associated with high affinity to the NP hapten (17% of Tg clones and 77% control clones had selected changes; Fig. 6Go; G test for goodness of fi, p < 0.001).



View larger version (29K):
[in this window]
[in a new window]
 
FIGURE 6. Mutation frequencies (mutations per clone; m/c) of immunized Tg and control mice. The full sequence of VH186.2 (including CDR3) was analyzed from B220+{lambda}+ cell-derived clones obtained 15 days after immunization with NP-Hy in alum. Each circle depicts a clone, and clones connected by a line represent clones with same CDR3 sharing at least one mutation. When most of the mutations were shared among clonally related sequences, only the highest mutated clone was considered for analysis of frequencies. •, Clones with the W to L change; among clonally related sequences, shared W to L changes were only counted once. , Clones with a K to R change at amino acid 58, which may possibly nullify affinity enhancement by the W to L change and which, when combined with glycine at position 99, represent a separate lineage of high affinity variants in the NP response (see Humoral immune responsiveness of Tg mice expressing antisense RNA to Pol {zeta}). Clones with the K to R change but without the glycine at position 99 were excluded from the analysis of selected changes, whereas those with the glycine were counted as a selected change.

 
Data from Tg mice-derived memory B cells in the day-30 fragment culture experiment mentioned above also revealed a lower frequency of mutation and of selected changes (4.3 mutations per clone, where 30% of the clones had the selected changes) when compared with control donors (6.2 mutations per clone, where 75% of the clones had the selected changes). Both control and Tg day-30 data showed a slightly higher mutation frequency than an equivalent group on day 15, which may reflect progressive accumulation of mutations over time after immunization.

Consistent with this increase in selected mutations, the binding to NP of the serum IgG Abs at day 30 was 50% inhibited at a mean concentration of ± 0.3 x 10-5, which is comparable to that seen for day-15 Abs from control animals.

Previous studies have shown the presence of a highly mutated memory B cell population with negligible levels of B220 on their surface (55). Thus, to ensure inclusion of this population in our analysis, {gamma} H chains from total spleen cells were analyzed from the fourth immunized Tg mouse (number 557) and the fourth control mouse sacrificed on day 15. Again, only clones with at least one mutation were considered (Tg, 14 of 16 clones were mutated; control, 17 of 17 clones were mutated). The control animal had a lower frequency of mutation and of selected changes than the sorted {lambda}+B220+ B cells from day-15 controls, which probably reflects the inclusion of a subset of B cells that exit the GC reaction early and participate in the primary response (56). Nevertheless, the Tg animal had a 43% lower mutation frequency than the similarly treated control (Tg, 2.4 mutations per mutated clone with 0% of clones with selected changes; control, 4.2 mutations per mutated clone with 29% of the clones containing the selected changes).

Although the mutation frequency is lower, the pattern of mutations generated by memory B cells of low Pol {zeta} animals is nearly identical with the pattern seen in the controls (Table IGo). Similarly, the majority of the mutations was concentrated to the CDRs in both groups (although more pronounced in the control CDR1 due to the W to L replacements). Close to half of the mutations in both Tg and controls occurred at the consensus hotspot motif RGYW. Furthermore, Tg mice had replacement:synonymous (r:s) ratios that were entirely consistent with both negative and positive selection (6). The r:s ratio in reading frame (RF)1 was 1.4, in RF2 was 2.7, and in RF3 was 2.3, whereas the ratio in CDR2 was 4.2, and there were 38 replacements but no synonymous changes in CDR1. Another important indication for selection in the NP response is the amino acid composition of CDR3 (53). Among clones in which the diversity element could be identified, 76% of Tg origin and 78% of control origin used the NP-response characteristic DFL16.1, mostly in RF1 and predominantly with the JH2 segment (Table IIGo).


View this table:
[in this window]
[in a new window]
 
Table I. Pattern of VH186.2 mutations in immunized Tg and control mice (excluding W to L mutations)

 

View this table:
[in this window]
[in a new window]
 
Table II. CDR3 sequences and W to L mutations at residue 33 in H chains of NP-Hy-immunized antisense Tg and control micea

 

    Discussion
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
To examine a potential role for Pol {zeta} in somatic hypermutation, we generated Tg mice that express antisense RNA to a portion of the catalytic subunit of the mouse REV3 gene. Although there is a significant reduction in the number of B cells generated in the bone marrow, these animals mounted vigorous humoral immune responses following immunization, formed large GCs, and generated comparable frequencies of memory B cells to control mice. However, by day 15, most failed to generate high affinity Abs. The overall frequency of somatic mutations and of selected changes in the VH186.2 gene was reduced in the six Tg animals when compared with similarly treated controls, which was reflective of a large population of poorly mutated clones (less than three mutations). Homozygosity of the Tg integration site is unlikely to explain the data presented here because animals heterozygous at both integration sites or homozygous at different integration sites converged on the same phenotype. Evidence for a lower frequency of overall mutation and especially of selected changes was observed by three different experimental approaches: sorting for {lambda}+B220+ cells, analysis of total spleen cells, and in vitro boosting of memory B cells in spleen fragment cultures.

One possible interpretation of this data is that we have interfered with the process of selection rather than mutation by introducing a defect in apoptosis. A reduced ability to undergo apoptosis may prevent the elimination of cells with low affinity receptors. Indeed, the magnitude of the decrease in selected changes and in somatic mutations in antisense Pol {zeta} mice is similar to that previously seen in mice that overexpress BCL-2 (57). However, in contrast to Pol {zeta}-reduced mice, BCL-2-Tg mice have a significant increase in the frequency of memory B cells (57). Additionally, although the FR r:s ratios in both antisense REV3 mice and BCL-2-Tg mice were consistent with negative selection against deleterious mutations (2.0 and 1.8, respectively), the CDR r:s ratios in antisense REV3 mice were very different from BCL-2-Tg mice (7.5 vs 2.9), suggesting ongoing positive selection in the REV3 antisense-Tg mice. Furthermore, although there is speculation that Pol {zeta} plays a role in apoptosis (35), there is no evidence that this polymerase plays a direct role in this process and, indeed, it would be unprecedented for a translesion synthesis polymerase to perform such a function.

Impaired proliferation due to a defect in replication could also account for the lower frequency of somatic hypermutation in these mice. The early lethality of the Pol {zeta} knockout may in fact reflect a defect in the replication of rapidly dividing cells carrying a large load of damaged DNA (39). However, yeast cells deficient in REV3 proceed with normal kinetics through S phase after exposure to the DNA-damaging agent cisplatin but arrest in G2 where DSB repair via homologous recombination can occur (58). In a separate study, REV3 mutant yeast cells were much more sensitive to damage in stationary-phase cells than in cells in exponential phase when exposed to both cisplatin and mechlorethamine, which generate interstrand cross-links (59).The evidence that Pol {zeta} introduces base substitutions near DSBs in yeast (37) suggests that this polymerase plays a role in DSB repair, and this function may be the cause of the early lethality of the knockout. Indeed, mice exhibiting inactivation of the DSB repair gene RAD50 also display early lethality (60). Finally, a defect in replication would be difficult to reconcile with the abundant and large GCs that antisense REV3 mice formed. There is a precedent in the literature for the impact that impaired proliferation has on GC structure: mice deficient in mismatch repair genes generate small and few GCs due to microsatellite instability and reduced proliferative potential (61).

The third interpretation of these data is that Pol {zeta} plays a direct role in the process of somatic hypermutation. The fact that we did not completely abolish Pol {zeta} in these animals may have resulted in a sluggish Ig hypermutation machinery, whereby hypermutation-introduced DSBs may have been repaired much more inefficiently, both via error-free synthesis or with the residual Pol {zeta} molecules the B cells may have contained, thereby reducing the rate of somatic hypermutation and delaying affinity maturation. In support of this notion, serum Abs from Tg mice analyzed 30 days after immunization had affinities comparable to that of controls. It has been proposed that the hypermutation rate needs to be sufficiently high to allow for the acquisition of specific affinity-enhancing mutations but limited by the probability for introduction of mutations deleterious to the structure of the receptor or affinity (62, 63). This model predicts that, with a decreased rate of hypermutation, the probability of obtaining an affinity-enhancing mutation is low and, because fewer cells would have negatively impacted receptors from mutation, GCs would be large and persistent. This model would particularly apply to the {lambda} response to the NP hapten, wherein a single mutation (W to L) in CDR1 has such a profound impact on affinity. Thus, the lower frequency of clones with selected changes and the larger GCs in the Tg mice may reflect a lower rate of hypermutation. Our data may in fact represent the first evidence that the rate of hypermutation is critical to the kinetics of affinity maturation, at least in the case of the NP response, and these data may be unobtainable in a case in which somatic hypermutation is completely disrupted.

We did not observe an alteration in the pattern of mutations in conjunction with the decreased mutation frequency, and this result may reflect a role of Pol {zeta} in extending synthesis from a mismatched terminus, as recent studies have demonstrated (34, 36). In fact, it is likely that what makes Pol {zeta} an integral component of error-prone synthesis is its remarkable ability to extend from a mismatched terminus created by other more error-prone polymerases (such as {eta} and {iota}; 34, 36). Thus, reducing the levels of the "mismatch extender" should impact all mutations similarly, resulting in a reduction in the frequency of mutation without an altering of the pattern of mutations.

Here we have tested a putative role for Pol {zeta} in somatic hypermutation of Ig V genes by generating mice with low levels of this polymerase. However, the intimate relationship between somatic hypermutation and affinity maturation makes it difficult to separate a defect in somatic hypermutation from a defect in clonal selection. Therefore, we cannot formally rule out a subtle defect in clonal selection. However, because both negative selection and positive selection appear intact as revealed by the CDR and RF r:s ratios and the usage of the anti-NP prototypical CDR3, the findings presented here are most consistent with a direct role of Pol {zeta} in the mechanism of somatic hypermutation.


    Acknowledgments
 
We thank Alice Cheng, Samantha Zaharevitz, and Nora Leaf for technical assistance. We are also grateful to David Nemazee for comments on the manuscript, to Chris Lawrence for stimulating discussions on somatic hypermutation and Pol {zeta}, and to David Schatz for discussions on Ig hypermutation double-strand breaks.


    Footnotes
 
1 This work was supported by Grant AI-15797 from National Institute of Allergy and Infectious Diseases, National Institutes of Health. M.D. was a Burroughs Wellcome Fund Fellow of the Life Sciences Research Foundation for part of this work and is currently supported by National Institutes of Health Training Grant T32 A1-07244. L.K.V. is a Terry Fox Postdoctoral Fellow of the National Cancer Institute of Canada. Back

2 Address correspondence and reprint requests to Dr. Marilyn Diaz, Department of Immunology, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037. E-mail address: mdiaz{at}scripps.edu Back

3 Abbreviations used in this paper: GC, germinal center; DSB, double-strand break; Pol {zeta}, DNA polymerase {zeta}; Tg, transgenic; Hy, Limulus polyphemus hemocyanin; NP, (4-hydroxy-3 nitrophenyl)acetyl; HPRT, hypoxanthine phosphoribosyltransferase; PNA, peanut lectin agglutinin; CDR, complementarity-determining region; r:s, replacement:synonymous; RF, reading frame; mREV3, mouse REV3. Back

Received for publication January 23, 2001. Accepted for publication April 25, 2001.


    References
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Eisen, H. N., G. W. Siskind. 1964. Variations in affinities of antibodies during the immune response. Biochemistry 3:996.
  2. Klinman, N. R., J. H. Rockey, G. Fraunenberger, F. Karush. 1966. Equine anti-hapten antibody. 3. The comparative properties of {gamma}G- and {gamma}A-antibodies. J. Immunol. 96:587.[Abstract/Free Full Text]
  3. Klinman, N. R.. 1972. The mechanism of antigenic stimulation of primary and secondary clonal precursor cells. J. Exp. Med. 136:241.[Abstract]
  4. Weigert, M. G., I. M. Cesari, S. J. Yonkovich, M. Cohn. 1970. Variability in the {lambda} light chain sequences of mouse antibody. Nature 228:1045.[Medline]
  5. Crews, S., J. Griffin, C. K. Huang, L. Hood. 1981. A single VH gene segment encodes the immune response to phosphorylcholine: somatic mutation is correlated with the class of the antibody. Cell 25:59.[Medline]
  6. Clarke, S. H., K. Huppi, D. Ruezinski, L. Staudt, W. Gerhard, M. Weigert. 1985. Inter- and intraclonal diversity in the antibody response to influenza hemagglutinin. J. Exp. Med. 161:687.[Abstract/Free Full Text]
  7. Manser, T., L. J. Wysocki, M. N. Margolies, M. L. Gefter. 1987. Evolution of antibody variable region structure during the immune response. Immunol. Rev. 96:141.[Medline]
  8. Berek, C., C. Milstein. 1987. Mutation drift and repertoire shift in the maturation of the immune response. Immunol. Rev. 96:23.[Medline]
  9. Allen, D., A. Cumano, R. Dildrop, C. Kocks, K. Rajewsky, N. Rajewsky, J. Roes, F. Sablitzky, M. Siekevitz. 1987. Timing, genetic requirements and functional consequences of somatic hypermutation during B-cell development. Immunol. Rev. 96:5.[Medline]
  10. Berek, C., A. Beige, M. Apel. 1991. Maturation of the immune response in germinal centers. Cell 67:1121.[Medline]
  11. Betz, A., C. Milstein, R. Gonzalez-Fernandez, R. Pannell, T. Larson, M. Neuberger. 1994. Elements regulating somatic hypermutation of an immunoglobulin {kappa} gene: critical role for the intron enhancer/matrix attachment region. Cell 77:239.[Medline]
  12. Bachl, J., M. Wabl. 1996. Enhancers of hypermutation. Immunogenetics 45:59.[Medline]
  13. Peters, A., U. Storb. 1996. Somatic hypermutation of immunoglobulin genes is linked to transcription initiation. Immunity 4:57.[Medline]
  14. Sale, J. E., M. S. Neuberger. 1998. TdT-accessible breaks are scattered over the immunoglobulin V domain in a constitutively hypermutating B cell line. Immunity 9:859.[Medline]
  15. Papavasiliou, F. N., D. G. Schatz. 2000. Cell-cycle-regulated DNA double-stranded breaks in somatic hypermutation of immunoglobulin genes. Nature 408:216.[Medline]
  16. Bross, L., Y. Fukita, F. McBlane, C. Demolliere, K. Rajewsky, H. Jacobs. 2001. DNA double-strand breaks in immunoglobulin genes undergoing somatic hypermutation. Immunity 13:589.
  17. Muramatsu, M., K. Kinoshita, S. Fagarasan, S. Yamada, Y. Shinkai, T. Honjo. 2000. Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme. Cell 1102:553.
  18. Sharpe, M., C. Milstein, J. M. Jarvis, M. S. Neuberger. 1991. Somatic hypermutation of immunoglobulin {kappa} may depend on sequences 3' of C{kappa} and occurs in passenger transgenes. EMBO J. 10:2139.[Medline]
  19. Diaz, M., J. Velez, M. Singh, J. Cerny, M. F. Flajnik. 1999. Mutational pattern of the nurse shark antigen receptor gene (NAR) is similar to that of mammalian Ig genes and to spontaneous mutations in evolution: the translesion synthesis model of somatic hypermutation. Int. Immunol. 11:825.[Abstract/Free Full Text]
  20. Dorner, T., H-P. Brezinscheck, R. I. Brezinscheck, S. J. Foster, R. Domiati-Saad, P. E. Lipsky. 1997. Analysis of the frequency and pattern of somatic mutations with non-productively rearranged human variable chain genes. J. Immunol. 158:2779.[Abstract]
  21. Reynaud, C-A., A. Danhan, V. Anquez, J-C. Weill. 1989. Somatic hyperconversion diversifies the single VH gene of the chicken with a high incidence in the D region. Cell 59:171.[Medline]
  22. Wilson, M., E. Hsu, A. Marcuz, M. Courtet, L. Du Pasquier, C. Steinberg. 1992. What limits affinity maturation of antibodies in Xenopus–the rate of somatic mutation or the ability to select mutants?. EMBO J. 11:4337.[Medline]
  23. Rogozin, I. B., N. E. Sredneva, N. A. Kolchanov. 1996. Somatic hypermutagenesis in immunoglobulin genes. III. Somatic mutation in the chicken light chain locus. Biochim. Biophys. Acta 1306:171.[Medline]
  24. Golding, G. B., P. S. Gearhart, B. W. Glickman. 1987. Pattern of somatic mutations in immunoglobulin variable genes. Genetics 115:169.[Abstract/Free Full Text]
  25. Gonzalez-Fernandez, A., S. K. Gupta, R. Pannell, M. S. Neuberger, C. Milstein. 1994. Somatic mutation of immunoglobulin {lambda} chains: a segment of the major intron hypermutates as much as the complementarity-determining regions. Proc. Natl. Acad. Sci. USA 91:12614.[Abstract/Free Full Text]
  26. Storb, U., E. L. Klotz, J. Hackett, K. Kage, G. Bozek, T. E. Martin. 1998. A hypermutable insert in an immunoglobulin transgene contains hotspots of somatic mutation and sequences predicting highly stable structures in the RNA transcript. J. Exp. Med. 188:689.[Abstract/Free Full Text]
  27. Wilson, P. C., O. de Bouteiller, Y. J. Liu, K. Potter, J. Banchereau, J. D. Capra, V. Pascual. 1998. Somatic hypermutation introduces insertions and deletions into immunoglobulin V genes. J. Exp. Med. 187:59.[Abstract/Free Full Text]
  28. Greenberg, A. S., D. Avila, M. Hughes, A. Hughes, E. C. McKinney, M. F. Flajnik. 1995. New antigen receptor gene family that undergoes rearrangement and extensive somatic diversification in sharks. Nature 374:168.[Medline]
  29. Brenner, S., C. Milstein. 1966. Origin of antibody variation. Nature 211:242.[Medline]
  30. Diaz, M., M. F. Flajnik. 1998. Evolution of somatic hypermutation and gene conversion in adaptive immunity. Immunol. Rev. 162:13.[Medline]
  31. Diaz, M., M. F. Flajnik, N. Klinman. 2001. Evolution and the molecular basis of somatic hypermutation of antigen receptor genes. Philos. Trans. R. Soc. London B 356:67.[Abstract/Free Full Text]
  32. Nelson, J. R., C. W. Lawrence, D. C. Hinckle. 1996. Thymine-thymine dimer bypass by yeast DNA polymerase {zeta}. Science 272:1646.[Abstract]
  33. Gibbs, P. E. M., W. G. McGregor, V. Maher, P. Nisson, C. W. Lawrence. 1988. A human homolog of the Saccharomyces cerevisiae REV3 gene, which encodes the catalytic subunits of DNA polymerase {zeta}. Proc. Natl. Acad. Sci. USA 95:6876.[Abstract/Free Full Text]
  34. Johnson, R. E., M. T. Washington, L. Haracska, S. Prakash, L. Prakash. 2000. Eukaryotic polymerases {iota} and {zeta} act sequentially to bypass DNA lesions. Nature 406:1015.[Medline]
  35. Lawrence, C. W., P. E. M. Gibbs, R. S. Murante, X-D. Wang, Z. Li, T. P. McManus, W. G. McGregor, J. R. Nelson, D. C. Hinckle, and V. M. Maher. Roles of DNA polymerase {zeta} and Rev1 protein in eukaryotic mutagenesis and translesion replication. Cold Spring Harbor Symp. Quant. Biol. In press.
  36. Yuan, F., Y. Zhang, D. K. Rajpal, X. Wu, D. Guo, M. Wang, J. S. Taylor, Z. Wang. 2000. Specificity of DNA lesion bypass by the yeast DNA polymerase eta. J. Biol. Chem. 17:8233.
  37. Holbeck, S. L., J. N. Strathern. 1997. A role for REV3 in mutagenesis during double-strand break repair in Saccharomyces cerevisiae. Genetics 147:1017.[Abstract]
  38. Esposito, G., I. Godindagger, U. Klein, M. Yaspo, A. Cumano, K. Rajewsky. 2000. Disruption of the Rev3l-encoded catalytic subunit of polymerase {zeta} in mice results in early embryonic lethality. Curr. Biol. 10:1221.[Medline]
  39. Wittschieben, J., M. K. Shivji, E. Lalani, M. A. Jacobs, F. Marini, P. J. Gearhart, I. Rosewell, G. Stamp, R. D. Wood. 2000. Disruption of the developmentally regulated rev3l gene causes embryonic lethality. Curr. Biol. 10:1217.[Medline]
  40. Bemark, M., A. A. Khamlichi, S. L. Davies, M. S. Neuberger. 2000. Disruption of mouse polymerase {zeta} (Rev3) leads to embryonic lethality and impairs blastocyst development in vitro. Curr. Biol. 10:1213.[Medline]
  41. Kinoshita, S., H. Suzuki, K. Ito, K. Kume, T. Shimizu, Y. Sugiyama. 1998. Transfected rat cMOAT is functionally expressed on the apical membrane in Madin-Darby canine kidney (MDCK) cells. Pharm. Res. 15:1851.[Medline]
  42. Verkoczy, L. K., P. A. Marsden, N. L. Berinstein. 1998. hBRAG, a novel B cell lineage cDNA encoding a type II transmembrane glycoprotein potentially involved in the regulation of recombination activating gene 1 (RAG1). Eur. J. Immunol. 28:2839.[Medline]
  43. Riley, R. L., N. R. Klinman. 1985. Differences in antibody repertoire for (4-hydroxy-3-nitrophenyl)acetyl (NP) in splenic vs immature bone marrow precursor cells. J. Immunol. 135:3050.[Abstract]
  44. Jacks, R. S., T. Imanishi-Kari, K. Rajewsky. 1977. Idiotypic analysis of the response of C57BL/6 mice to the (4-hydroxy-3-nitrophenyl)acetyl group. Eur. J. Immunol. 8:559.
  45. Liu, F. T., J. W. Bohn, E. L. Ferry, H. Yamamoto, C. A. Molinaro, L. A. Sherman, N. R. Klinman, D. H. Katz. 1980. Monoclonal dinitrophenyl-specific murine IgE antibody: preparation, isolation, and characterization. J. Immunol. 124:2728.[Medline]
  46. Froscher, B. G., N. R. Klinman. 1987. Splenic focus assay. Methods Enzymol. 150:196.[Medline]
  47. Sokal, R. L., F. J. Rohlf. 1981. Biometry: The Principles and Practice of Statistics in Biological Research, 2nd Ed W. H. Freeman and Company, New York.
  48. Lipman, D. J.. 1997. Making (anti)sense of non-coding sequence conservation. Nucleic Acids Res. 25:3580.[Abstract/Free Full Text]
  49. Kumar, M., G. G. Carmichael. 1998. Antisense RNA: Function and fate of duplex RNA in cells of higher eukaryotes. Microbiol. Mol. Biol. Rev. 62:1415.[Abstract/Free Full Text]
  50. Celano, P., C. M. Berchtold, D. L. Kizer, A. Weeraratna, B. D. Nelkin, S. B. Baylin, Jr R. A. Casero. 1992. Characterization of an endogenous RNA transcript with homology to the antisense strand of the human c-myc gene. J. Biol. Chem. 267:15092.[Abstract/Free Full Text]
  51. Makela, O., K. Karajalainen. 1977. Inherited immunoglobulin idiotypes of the mouse. Immunol. Rev. 345:119.
  52. Cumano, A., K. Rajewsky. 1986. Structure of primary anti-(4-hydroxy-3-nitrophenyl)acetyl (NP) antibodies in normal and idiotypically supressed C57BL/6 mice. EMBO J. 5:2459.[Medline]
  53. Furukawa, K., A. Akasako-Furukawa, H. Shirai, H. Nakamura, T. Azuma. 1999. Junctional amino acids determine the maturation pathway of an antibody. Immunity 11:329.[Medline]
  54. Zharhary, D., N. R. Klinman. 1986. A selective increase in the generation of phosphorylcholine-specific B cells associated with aging. J. Immunol. 136:368.[Medline]
  55. McHeyzer-Williams, L. J., M. Cool, M. G. McHeyzer-Williams. 2000. Antigen-specifc B cell memory: expression and replenishment of a novel B220- memory B cell compartment. J. Exp. Med. 191:1149.[Abstract/Free Full Text]
  56. Linton, P. J., D. J. Decker, N. R. Klinman. 1989. Primary antibody-forming cells and secondary B cells are generated from separate precursor cell subpopulations. Cell 59:1049.[Medline]
  57. Smith, K. G., A. Light, L. A. O’Reilly, S. M. Ang, A. Strasser, D. Tarlinton. 2000. Bcl-2 transgene expression inhibits apoptosis in the germinal center and reveals differences in the selection of memory B cells and bone marrow antibody-forming cells. J. Exp. Med. 191:475.[Abstract/Free Full Text]
  58. Grossmann, K. F., A. M. Ward, R. E. Moses. 2000. Saccharomyces cerevisiae lacking snm1, rev3 or rad51 have a normal S-phase but arrest permanently in G2 after cisplatin treatment. Mutat. Res. 461:1.[Medline]
  59. McHugh, P. J., W. R. Sones, J. A. Hartley. 2000. Repair of intermediate structures produced at DNA interstrand cross-links in Saccharomyces cerevisiae. Mol. Cell. Biol. 20:3425.[Abstract/Free Full Text]
  60. Luo, G., M. S. Yao, C. F. Bender, M. Mills, A. R. Bladl, A. Bradley, J. H. Petrini. 1999. Disruption of mRad50 causes embryonic stem cell lethality, abnormal embryonic development, and sensitivity to ionizing radiation. Proc. Natl. Acad. Sci. USA 96:7376.[Abstract/Free Full Text]
  61. Vora, K. A., K. M. Tumas-Brundage, V. M. Lentz, A. Cranston, R. Fishel, T. Manser. 1999. Severe attenuation of the B cell immune response in Msh2-deficient mice. J. Exp. Med. 189:471.[Abstract/Free Full Text]
  62. Schlomchik, M. J., P. Watts, M. Weigert, S. Litwin. 1998. Clone: a Monte-Carlo computer simulation of B cell clonal expansion, somatic mutation, and antigen-driven selection. Curr. Top. Microbiol. Immunol. 229:173.[Medline]
  63. Schlomchik, M. J., S. Litwin, M. Weigert. 1989. Progress in Immunology VII Springer, New York.



This article has been cited by other articles:


Home page
Mol. Cell. Biol.Home page
D. Frieder, M. Larijani, C. Collins, M. Shulman, and A. Martin
The Concerted Action of Msh2 and UNG Stimulates Somatic Hypermutation at A {middle dot} T Base Pairs
Mol. Cell. Biol., September 15, 2009; 29(18): 5148 - 5157.
[Abstract] [Full Text] [PDF]


Home page
Nucleic Acids ResHome page
J. E. Stone, G. E. Kissling, S. A. Lujan, I. B. Rogozin, C. M. Stith, P. M. J. Burgers, and T. A. Kunkel
Low-fidelity DNA synthesis by the L979F mutator derivative of Saccharomyces cerevisiae DNA polymerase {zeta}
Nucleic Acids Res., June 1, 2009; 37(11): 3774 - 3787.
[Abstract] [Full Text] [PDF]


Home page
Phil Trans R Soc BHome page
H. Saribasak, D. Rajagopal, R. W Maul, and P. J Gearhart
Hijacked DNA repair proteins and unchained DNA polymerases
Phil Trans R Soc B, March 12, 2009; 364(1517): 605 - 611.
[Abstract] [Full Text] [PDF]


Home page
Phil Trans R Soc BHome page
P. Langerak, P. H.L Krijger, M. R Heideman, P. C.M van den Berk, and H. Jacobs
Somatic hypermutation of immunoglobulin genes: lessons from proliferating cell nuclear antigenK164R mutant mice
Phil Trans R Soc B, March 12, 2009; 364(1517): 621 - 629.
[Abstract] [Full Text] [PDF]


Home page
JEMHome page
D. Schenten, S. Kracker, G. Esposito, S. Franco, U. Klein, M. Murphy, F. W. Alt, and K. Rajewsky
Pol{zeta} ablation in B cells impairs the germinal center reaction, class switch recombination, DNA break repair, and genome stability
J. Exp. Med., February 16, 2009; 206(2): 477 - 490.
[Abstract] [Full Text] [PDF]


Home page
GeneticsHome page
E. Mito, J. V. Mokhnatkin, M. C. Steele, V. L. Buettner, S. S. Sommer, G. M. Manthey, and A. M. Bailis
Mutagenic and Recombinagenic Responses to Defective DNA Polymerase {delta} Are Facilitated by the Rev1 Protein in pol3-t Mutants of Saccharomyces cerevisiae
Genetics, August 1, 2008; 179(4): 1795 - 1806.
[Abstract] [Full Text] [PDF]


Home page
JEMHome page
P. Langerak, A. O.H. Nygren, P. H.L. Krijger, P. C.M. van den Berk, and H. Jacobs
A/T mutagenesis in hypermutated immunoglobulin genes strongly depends on PCNAK164 modification
J. Exp. Med., August 6, 2007; 204(8): 1989 - 1998.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
K. Masuda, R. Ouchida, M. Hikida, T. Kurosaki, M. Yokoi, C. Masutani, M. Seki, R. D. Wood, F. Hanaoka, and J. O-Wang
DNA Polymerases {eta} and {theta} Function in the Same Genetic Pathway to Generate Mutations at A/T during Somatic Hypermutation of Ig Genes
J. Biol. Chem., June 15, 2007; 282(24): 17387 - 17394.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
L. Ohm-Laursen and T. Barington
Analysis of 6912 Unselected Somatic Hypermutations in Human VDJ Rearrangements Reveals Lack of Strand Specificity and Correlation between Phase II Substitution Rates and Distance to the Nearest 3' Activation-Induced Cytidine Deaminase Target
J. Immunol., April 1, 2007; 178(7): 4322 - 4334.
[Abstract] [Full Text] [PDF]


Home page
JEMHome page
F. Delbos, S. Aoufouchi, A. Faili, J.-C. Weill, and C.-A. Reynaud
DNA polymerase {eta} is the sole contributor of A/T modifications during immunoglobulin gene hypermutation in the mouse
J. Exp. Med., January 22, 2007; 204(1): 17 - 23.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
J. Bachl, I. Ertongur, and B. Jungnickel
Involvement of Rad18 in somatic hypermutation
PNAS, August 8, 2006; 103(32): 12081 - 12086.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
R. Takeuchi, T. Ruike, R.-i. Nakamura, K. Shimanouchi, Y. Kanai, Y. Abe, A. Ihara, and K. Sakaguchi
Drosophila DNA Polymerase {zeta} Interacts with Recombination Repair Protein 1, the Drosophila Homologue of Human Abasic Endonuclease 1
J. Biol. Chem., April 28, 2006; 281(17): 11577 - 11585.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
J. P. Wittschieben, S. C. Reshmi, S. M. Gollin, and R. D. Wood
Loss of DNA Polymerase {zeta} Causes Chromosomal Instability in Mammalian Cells
Cancer Res., January 1, 2006; 66(1): 134 - 142.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
J. Spencer and D. K. Dunn-Walters
Hypermutation at A-T Base Pairs: The A Nucleotide Replacement Spectrum Is Affected by Adjacent Nucleotides and There Is No Reverse Complementarity of Sequences Flanking Mutated A and T Nucleotides
J. Immunol., October 15, 2005; 175(8): 5170 - 5177.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
K. Masuda, R. Ouchida, A. Takeuchi, T. Saito, H. Koseki, K. Kawamura, M. Tagawa, T. Tokuhisa, T. Azuma, and J. O-Wang
DNA polymerase {theta} contributes to the generation of C/G mutations during somatic hypermutation of Ig genes
PNAS, September 27, 2005; 102(39): 13986 - 13991.
[Abstract] [Full Text] [PDF]


Home page
J. Virol.Home page
K. Machida, K. T.-H. Cheng, N. Pavio, V. M.-H. Sung, and M. M. C. Lai
Hepatitis C Virus E2-CD81 Interaction Induces Hypermutation of the Immunoglobulin Gene in B Cells
J. Virol., July 1, 2005; 79(13): 8079 - 8089.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
S. A. Martomo, W. W. Yang, R. P. Wersto, T. Ohkumo, Y. Kondo, M. Yokoi, C. Masutani, F. Hanaoka, and P. J. Gearhart
Different mutation signatures in DNA polymerase {eta}- and MSH6-deficient mice suggest separate roles in antibody diversification
PNAS, June 14, 2005; 102(24): 8656 - 8661.
[Abstract] [Full Text] [PDF]


Home page
JEMHome page
N.-Y. Zheng, K. Wilson, M. Jared, and P. C. Wilson
Intricate targeting of immunoglobulin somatic hypermutation maximizes the efficiency of affinity maturation
J. Exp. Med., May 2, 2005; 201(9): 1467 - 1478.
[Abstract] [Full Text] [PDF]


Home page
JEMHome page
F. Delbos, A. De Smet, A. Faili, S. Aoufouchi, J.-C. Weill, and C.-A. Reynaud
Contribution of DNA polymerase {eta} to immunoglobulin gene hypermutation in the mouse
J. Exp. Med., April 18, 2005; 201(8): 1191 - 1196.
[Abstract] [Full Text] [PDF]


Home page
JEMHome page
T. M. Wilson, A. Vaisman, S. A. Martomo, P. Sullivan, L. Lan, F. Hanaoka, A. Yasui, R. Woodgate, and P. J. Gearhart
MSH2-MSH6 stimulates DNA polymerase {eta}, suggesting a role for A:T mutations in antibody genes
J. Exp. Med., February 22, 2005; 201(4): 637 - 645.
[Abstract] [Full Text] [PDF]


Home page
Nucleic Acids ResHome page
J. F. Ruiz, D. Lucas, E. Garcia-Palomero, A. I. Saez, M. A. Gonzalez, M. A. Piris, A. Bernad, and L. Blanco
Overexpression of human DNA polymerase {micro} (Pol {micro}) in a Burkitt's lymphoma cell line affects the somatic hypermutation rate
Nucleic Acids Res., November 1, 2004; 32(19): 5861 - 5873.
[Abstract] [Full Text] [PDF]


Home page
JEMHome page
C. E. Schrader, J. Vardo, E. Linehan, M. Z. Twarog, L. J. Niedernhofer, J. H.J. Hoeijmakers, and J. Stavnezer
Deletion of the Nucleotide Excision Repair Gene Ercc1 Reduces Immunoglobulin Class Switching and Alters Mutations Near Switch Recombination Junctions
J. Exp. Med., August 2, 2004; 200(3): 321 - 330.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
S. S. Brar, M. Watson, and M. Diaz
Activation-induced Cytosine Deaminase (AID) Is Actively Exported out of the Nucleus but Retained by the Induction of DNA Breaks
J. Biol. Chem., June 18, 2004; 279(25): 26395 - 26401.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
I. B. Rogozin and M. Diaz
Cutting Edge: DGYW/WRCH Is a Better Predictor of Mutability at G:C Bases in Ig Hypermutation Than the Widely Accepted RGYW/WRCY Motif and Probably Reflects a Two-Step Activation-Induced Cytidine Deaminase-Triggered Process
J. Immunol., March 15, 2004; 172(6): 3382 - 3384.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
K. Kuwahara, S. Fujimura, Y. Takahashi, N. Nakagata, T. Takemori, S. Aizawa, and N. Sakaguchi
Germinal center-associated nuclear protein contributes to affinity maturation of B cell antigen receptor in T cell-dependent responses
PNAS, January 27, 2004; 101(4): 1010 - 1015.
[Abstract] [Full Text] [PDF]


Home page
Genes Dev.Home page
Z. Li, C. J. Woo, M. D. Iglesias-Ussel, D. Ronai, and M. D. Scharff
The generation of antibody diversity through somatic hypermutation and class switch recombination
Genes & Dev., January 1, 2004; 18(1): 1 - 11.
[Full Text] [PDF]


Home page
JEMHome page
A. Martin, Z. Li, D. P. Lin, P. D. Bardwell, M. D. Iglesias-Ussel, W. Edelmann, and M. D. Scharff
Msh2 ATPase Activity Is Essential for Somatic Hypermutation at A-T Basepairs and for Efficient Class Switch Recombination
J. Exp. Med., October 20, 2003; 198(8): 1171 - 1178.
[Abstract] [Full Text] [PDF]


Home page
Mol Cancer ResHome page
M. Diaz, N. B. Watson, G. Turkington, L. K. Verkoczy, N. R. Klinman, and W. G. McGregor
Decreased Frequency and Highly Aberrant Spectrum of Ultraviolet-Induced Mutations in the hprt Gene of Mouse Fibroblasts Expressing Antisense RNA to DNA Polymerase {zeta}
Mol. Cancer Res., September 1, 2003; 1(11): 836 - 847.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
D. B. Winter, Q. H. Phung, X. Zeng, E. Seeberg, D. E. Barnes, T. Lindahl, and P. J. Gearhart
Normal Somatic Hypermutation of Ig Genes in the Absence of 8-Hydroxyguanine-DNA Glycosylase
J. Immunol., June 1, 2003; 170(11): 5558 - 5562.
[Abstract] [Full Text] [PDF]


Home page
Int ImmunolHome page
A. Longacre, T. Sun, R. E. Goldsby, B. D. Preston, and U. Storb
Ig gene somatic hypermutation in mice defective for DNA polymerase {delta} proofreading
Int. Immunol., April 1, 2003; 15(4): 477 - 481.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
R. Bransteitter, P. Pham, M. D. Scharff, and M. F. Goodman
Activation-induced cytidine deaminase deaminates deoxycytidine on single-stranded DNA but requires the action of RNase
PNAS, April 1, 2003; 100(7): 4102 - 4107.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
Y.-F. Lu and J. Cerny
Repertoire of Antibody Response in Bone Marrow and the Memory Response Are Differentially Affected in Aging Mice
J. Immunol., November 1, 2002; 169(9): 4920 - 4927.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
Y. I. Pavlov, I. B. Rogozin, A. P. Galkin, A. Y. Aksenova, F. Hanaoka, C. Rada, and T. A. Kunkel
Correlation of somatic hypermutation specificity and A-T base pair substitution errors by DNA polymerase eta during copying of a mouse immunoglobulin kappa light chain transgene
PNAS, July 23, 2002; 99(15): 9954 - 9959.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
B. Bertocci, A. De Smet, E. Flatter, A. Dahan, J.-C. Bories, C. Landreau, J.-C. Weill, and C.-A. Reynaud
Cutting Edge: DNA Polymerases {micro} and {lambda} Are Dispensable for Ig Gene Hypermutation
J. Immunol., April 15, 2002; 168(8): 3702 - 3706.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Diaz, M.
Right arrow Articles by R. Klinman, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Diaz, M.
Right arrow Articles by R. Klinman, N.


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS